From Dream to Reality: A Scalable Solution for the Treatment of the Nano-rare | NRPC24 скачать в хорошем качестве

From Dream to Reality: A Scalable Solution for the Treatment of the Nano-rare | NRPC24

n-Lorem is developing a promising solution for nano-rare patients through the industrialization of personalized ASO medicines, establishing an infrastructure that seamlessly integrates expertise and processes. Sarah Glass, Ph.D., n-Lorem's Chief Operating Officer, shares how n-Lorem is turning what once seemed impossible into reality by creating a scalable approach to treat nano-rare patients. The presentation was given at the 2024 Nano-rare Patient Colloquium, hosted by Biogen, on October 31, in Cambridge, MA. Dr. Sarah Glass is the chief operating officer of n-Lorem Foundation. Sarah received her Ph.D. in Molecular Genetics at Ohio State University where she trained in rare inherited cancer syndromes. She has over 20 years of experience in clinical development and research across academia, pharmaceutical companies, and CROs. Sarah brings significant strengths and experience as an accomplished research geneticist, rare disease drug developer, and clinical trialist. She is acclaimed for forging key strategic partnerships across rare disease sectors and has driven efficiencies to decrease patient/caregiver burden in clinical research. Most notably, Sarah combines her professional expertise and training with the perspective of a parent of a child with a nano-rare disease. This allows Sarah to not only personally understand the challenges faced by n-Lorem patients and their families, but also to translate this understanding into n-Lorem’s paradigm shifting platform solution for the nano-rare community. Outside of n-Lorem, Sarah volunteers as chair of the DYRK1A Medical and Scientific advisory board and is engaged in many rare disease organizations to ensure collaboration in reaching common goals. https://www.nlorem.org/nano-rare-pati...